Company: STAA
Filing Date: 2025-12-11
Form Type: DEFA14A
Source: 0001193125-25-315272
Chunk: 3

Company: STAAR SURGICAL CO
Filing Date: 2025-12-11
Form: DEFA14A
Chunk 3
---
 on October 24, 2025, are entitled to vote at the meeting. The Alcon merger agreement, as revised on December 9, 2025, represents a 74% premium to STAAR’s 90-dayVolume Weighted Average Price and a 66% premium to the closing price of STAAR common stock on August 4, 2025. We encourage shareholders to reach their own informed conclusions based on the facts and to ensure their voices are heard at the special meeting. Stockholders with questions about voting their shares should contact STAAR’s proxy solicitor, Innisfree M&A Incorporated:

| • |     | For stockholders: +1 877-750-8233                                              
 (toll-free from the U.S. and Canada) or +1 412-232-3651 (from other countries) |

| • |     | For banks and brokerage firms: +1 
 212-750-5833                      |

About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer ®Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL ™product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.EVOICL.com. To learn more about STAAR, visit www.staar.com.

Additional Information About the Merger and Where to Find It

This communication relates to the proposed transaction involving STAAR. In connection with the proposed transaction, STAAR has filed relevant materials with
the U.S. Securities and Exchange Commission (the “SEC”), including STAAR’s definitive proxy statement on Schedule 14A (the “Proxy Statement”), on September 16, 2025. The Proxy Statement was first sent to STAAR
stockholders on